Handle, dispense and seal radioligand-therapy vials within shielded isolators/hot cells
Novartis' radioligand therapies (Pluvicto, Lutathera) are lutetium-177-based injectable doses produced under intense time pressure because the radioactive half-life is measured in hours and each dose is essentially custom-made for a specific patient. Manufacturing requires handling, filling/dispensing and crimp-sealing vials of radioactive material behind heavy shielding (hot cells/isolators) where human proximity must be minimized. The task involves precise grasping, placement and closure of small vials, applying controlled force to seat crimp caps/closures while maintaining sterility and containment. It is extremely hard because it demands remote dexterous manipulation under shielding with no easy human intervention, and Novartis has explicitly stated plans for fully automated lines as a first for the radiopharmaceutical industry. A single failure is unacceptable: it implies radioactive contamination, a sterile breach, and loss of an irreplaceable, decay-limited patient dose. We identified this through our own research; we have not confirmed the specifics with the customer directly. This page is our researched read — a starting point for that conversation.
What the task is
RESEARCHED · our reconstructionNovartis' radioligand therapies (Pluvicto, Lutathera) are lutetium-177-based injectable doses produced under intense time pressure because the radioactive half-life is measured in hours and each dose is essentially custom-made for a specific patient. Manufacturing requires handling, filling/dispensing and crimp-sealing vials of radioactive material behind heavy shielding (hot cells/isolators) where human proximity must be minimized. The task involves precise grasping, placement and closure of small vials, applying controlled force to seat crimp caps/closures while maintaining sterility and containment. It is extremely hard because it demands remote dexterous manipulation under shielding with no easy human intervention, and Novartis has explicitly stated plans for fully automated lines as a first for the radiopharmaceutical industry. A single failure is unacceptable: it implies radioactive contamination, a sterile breach, and loss of an irreplaceable, decay-limited patient dose.
Is this the actual task and sequence? What are the real tolerances, cycle rate, and reject criteria, and which steps are today's manual bottleneck? Answering these is what turns this from a researched signal into a validated use case.